Open Access
J Oral Med Oral Surg
Volume 26, Number 3, 2020
Article Number 35
Number of page(s) 7
Section Article original / Original article
Published online 26 August 2020
  1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1–211. [Google Scholar]
  2. Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA. Update on burning mouth syndrome: overview and patient management. Crit Rev Oral Biol Med 2003;14:275–291. [Google Scholar]
  3. Jääskeläinen SK, Woda A. Burning mouth syndrome. Cephalalgia 2017;37:627–647. [CrossRef] [PubMed] [Google Scholar]
  4. Kohorst JJ, Bruce AJ, Torgerson RR, Schenck LA, Davis MDP. The prevalence of burning mouth syndrome: a population-based study. Br J Dermatol 2015;172:1654–1656. [CrossRef] [PubMed] [Google Scholar]
  5. Grushka M, Sessle BJ. Burning mouth syndrome. Dent Clin North Am 1991;35:171–184. [PubMed] [Google Scholar]
  6. Périer J-M. History of Burning Mouth Syndrome (1800-1950): a review. Oral Dis 2018. [Google Scholar]
  7. Grushka M. Clinical features of burning mouth syndrome. Oral Surg Oral Med Oral Pathol 1987;63:30–36. [Google Scholar]
  8. Forssell H, Jääskeläinen S, List T, Svensson P, Baad-Hansen L. An update on pathophysiological mechanisms related to idiopathic oro-facial pain conditions with implications for management. J Oral Rehabil 2014. [Google Scholar]
  9. Jääskeläinen SK. Pathophysiology of primary burning mouth syndrome. Clin Neurophysiol 2012;123:71–77. [CrossRef] [PubMed] [Google Scholar]
  10. Kolkka-Palomaa M, Jääskeläinen SK, Laine MA, Teerijoki-Oksa T, Sandell M, Forssell H. Pathophysiology of primary burning mouth syndrome with special focus on taste dysfunction: a review. Oral Dis 2015;21:937–948. [CrossRef] [PubMed] [Google Scholar]
  11. Lauria G. Small fibre neuropathies. Curr Opin Neurol 2005;18:591–597. [CrossRef] [PubMed] [Google Scholar]
  12. Woda A, Dao T, Gremeau-Richard C. Steroid dysregulation and stomatodynia (burning mouth syndrome). [Google Scholar]
  13. Braud A, Boucher Y. The relationship between the clinical features of idiopathic burning mouth syndrome and self-perceived quality of life. J Oral Sci 2016;58:475–481. [CrossRef] [PubMed] [Google Scholar]
  14. Lamey PJ, Lewis MA. Oral medicine in practice: burning mouth syndrome. Br Dent J 1989;167:197–200. [CrossRef] [PubMed] [Google Scholar]
  15. Penza P, Majorana A, Lombardi R, Camozzi F, Bonadeo S, Sapelli P, et al. “Burning tongue” and “burning tip”: the diagnostic challenge of the burning mouth syndrome. Clin J Pain 2010;26:528–532. [CrossRef] [PubMed] [Google Scholar]
  16. Häggman-Henrikson B, Alstergren P, Davidson T, Högestätt ED, Östlund P, Tranaeus S, et al. Pharmacological treatment of oro-facial pain − health technology assessment including a systematic review with network meta-analysis. J Oral Rehabil 2017;44:800–826. [CrossRef] [PubMed] [Google Scholar]
  17. Imamura Y, Shinozaki T, Okada-Ogawa A, Noma N, Shinoda M, Iwata K, et al. An updated review on pathophysiology and management of burning mouth syndrome with endocrinological, psychological and neuropathic perspectives. J Oral Rehabil 2019;46:574–587. [CrossRef] [PubMed] [Google Scholar]
  18. Kim Y, Yoo T, Han P, Liu Y, Inman JC. A pragmatic evidence-based clinical management algorithm for burning mouth syndrome. J Clin Exp Dent 2018;10:e321–e326. [PubMed] [Google Scholar]
  19. Liu YF, Kim Y, Yoo T, Han P, Inman JC. Burning mouth syndrome: a systematic review of treatments. Oral Dis 2017. [Google Scholar]
  20. McMillan R, Forssell H, Buchanan JA, Glenny A-M., Weldon JC, Zakrzewska JM. Interventions for treating burning mouth syndrome. Cochrane Database Syst Rev 2016;11:CD002779. [PubMed] [Google Scholar]
  21. Ritchie A, Kramer JM. Recent advances in the etiology and treatment of burning mouth syndrome. J Dent Res 2018:22034518782462. [Google Scholar]
  22. de Souza IF, Mármora BC, Rados PV, Visioli F. Treatment modalities for burning mouth syndrome: a systematic review. Clin Oral Investig 2018;22:1893–905. [PubMed] [Google Scholar]
  23. Zakrzewska JM, Forssell H, Glenny AM. Interventions for the treatment of burning mouth syndrome. Cochrane Database Syst Rev 2005:CD002779. [PubMed] [Google Scholar]
  24. Lamey P-J., Freeman R, Eddie S-A., Pankhurst C, Rees T. Vulnerability and presenting symptoms in burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:48–54. [CrossRef] [PubMed] [Google Scholar]
  25. Oghli I, List T, John M, Larsson P. Prevalence and oral health-related quality of life of self-reported orofacial conditions in Sweden. Oral Dis 2017;23:233–240. [CrossRef] [PubMed] [Google Scholar]
  26. Adamo D, Schiavone V, Aria M, Leuci S, Ruoppo E, Dell'Aversana G, et al. Sleep disturbance in patients with burning mouth syndrome: a case-control study. J Orofac Pain 2013;27:304–313. [CrossRef] [PubMed] [Google Scholar]
  27. Chainani-Wu N, Madden E, Silverman S. A case-control study of burning mouth syndrome and sleep dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:203–208. [CrossRef] [PubMed] [Google Scholar]
  28. Galli F, Lodi G, Sardella A, Vegni E. Role of psychological factors in burning mouth syndrome: a systematic review and meta-analysis. Cephalalgia 2017;37:265–77. [CrossRef] [PubMed] [Google Scholar]
  29. Mignogna MD, Pollio A, Fortuna G, Leuci S, Ruoppo E, Adamo D, et al. Unexplained somatic comorbidities in patients with burning mouth syndrome: a controlled clinical study. J Orofac Pain 2011;25:131–140. [PubMed] [Google Scholar]
  30. Moisset X, Calbacho V, Torres P, Gremeau-Richard C, Dallel R. Co-occurrence of pain symptoms and somatosensory sensitivity in burning mouth syndrome: a systematic review. PLoS One 2016;11. [Google Scholar]
  31. van der Ploeg HM, van der Wal N, Eijkman MA, van der Waal I. Psychological aspects of patients with burning mouth syndrome. Oral Surg Oral Med Oral Pathol 1987;63:664–668. [Google Scholar]
  32. Schirmer RH, Adler H, Pickhardt M, Mandelkow E. Lest we forget you–methylene blue. Neurobiol Aging 2011;32:2325.e7–16. [Google Scholar]
  33. Baldo CF, Silva LM, Arcencio L, Albuquerque AAS, Celotto AC, Evora* AB-F and PRB. Why methylene blue have to be always present in the stocking of emergency antidotes. Current Drug Targets 2018. (accessed June 20, 2019). [Google Scholar]
  34. Kallewaard JW, Wintraecken VM, Geurts JW, Willems PC, van Santbrink H, Terwiel CTM, et al. A multicenter randomized controlled trial on the efficacy of intradiscal methylene blue injection for chronic discogenic low back pain: the IMBI study. Pain 2019;160:945–953. [CrossRef] [PubMed] [Google Scholar]
  35. Peng B, Zhang Y, Hou S, Wu W, Fu X. Intradiscal methylene blue injection for the treatment of chronic discogenic low back pain. Eur Spine J 2007;16:33–38. [CrossRef] [PubMed] [Google Scholar]
  36. Fransiska D, Jeo WS, Moenadjat Y, Friska D. Methylene blue effectiveness as local analgesic after anorectal surgery: a literature review. Adv Med 2017;2017:3968278. [PubMed] [Google Scholar]
  37. Tan KY, Seow-Choen F. Methylene blue injection reduces pain after lateral anal sphincterotomy. Tech Coloproctol 2007;11:68–69. [PubMed] [Google Scholar]
  38. Tataru AP, Warrick BJ, Smolinske S. A systematic analysis of methylene blue for drug-induced shock in humans. Clin Toxicol (Phila) 2017;55:228. [PubMed] [Google Scholar]
  39. Zakaria ZA, Sulaiman MR, Somchit MN, Jais AMM, Ali DI. The effects of L-arginine, D-arginine, L-name and methylene blue on channa striatus-induced peripheral antinociception in mice. J Pharm Pharm Sci 2005;8:199–206. [Google Scholar]
  40. Zhao P, Mei L, Wang W. Clinical study of ultrasound-guided methylene blue thoracic paravertebral nerve block for the treatment of postherpetic neuralgia. Turk Neurosurg 2018. [PubMed] [Google Scholar]
  41. Eusebio E, Graham J, Mody N. Treatment of intractable pruritus ani. Diseases of the Colon Rectum 1990;33 770–772. [CrossRef] [Google Scholar]
  42. Farouk R, Lee PW. Intradermal methylene blue injection for the treatment of intractable idiopathic pruritus ani. Br J Surg 1997;84:670. [CrossRef] [PubMed] [Google Scholar]
  43. Mentes BB, Akin M, Leventoglu S, Gultekin FA, Oguz M. Intradermal methylene blue injection for the treatment of intractable idiopathic pruritus ani: results of 30 cases. Tech Coloproctol 2004;8:11–14. [PubMed] [Google Scholar]
  44. Sutherland AD, Faragher IG, Frizelle FA. Intradermal injection of methylene blue for the treatment of refractory pruritus ani. Colorectal Dis 2009;11:282–287. [CrossRef] [PubMed] [Google Scholar]
  45. Wolloch Y, Dintsman M. A simple and effective method of treatment for intractable pruritus ani. Am J Proctol Gastroenterol Colon Rectal Surg 1979;30:34–36. [Google Scholar]
  46. Dondas A, Luca A, Alexa T, Grigoras V, Mungiu O, Bohotin C. Repeated methylene blue administration produces analgesia in experimental pain. J Headache Pain 2013;14:P86. [Google Scholar]
  47. Aghahosseini F, Arbabi-Kalati F, Fashtami LA, Fateh M, Djavid GE. Treatment of oral lichen planus with photodynamic therapy mediated methylene blue: a case report. Med Oral Patol Oral Cir Bucal 2006;11:E126–E129. [Google Scholar]
  48. Roldan CJ, Nouri K, Chai T, Huh B. Methylene blue for the treatment of intractable pain associated with oral mucositis. Pain Pract 2017;17:1115–1121. [Google Scholar]
  49. Miclescu AA, Svahn M, Gordh TE. Evaluation of the protein biomarkers and the analgesic response to systemic methylene blue in patients with refractory neuropathic pain: a double-blind, controlled study. J Pain Res 2015;8:387–397. [CrossRef] [PubMed] [Google Scholar]
  50. Misery L, Brenaut E, Le Garrec R, Abasq C, Genestet S, Marcorelles P, et al. Neuropathic pruritus. Nat Rev Neurol 2014;10:408–416. [CrossRef] [PubMed] [Google Scholar]
  51. Vaccaro A, Patten SA, Ciura S, Maios C, Therrien M, Drapeau P, et al. Methylene blue protects against TDP-43 and FUS neuronal toxicity in C. elegans and D. rerio . PLOS ONE 2012;7:e42117. [CrossRef] [PubMed] [Google Scholar]
  52. Sim H-L., Tan K-Y. Randomized single-blind clinical trial of intradermal methylene blue on pain reduction after open diathermy haemorrhoidectomy. Colorectal Dis 2014;16:O283–287. [CrossRef] [PubMed] [Google Scholar]
  53. Sadaksharam J, Nayaki KPT, Selvam NP. Treatment of oral lichen planus with methylene blue mediated photodynamic therapy − a clinical study. Photodermatol Photoimmunol Photomed 2012;28:97–101. [CrossRef] [PubMed] [Google Scholar]
  54. Milazzo-Kiedaisch CA, Itano J, Dutta PR. The novel role of gabapentin in managing mucositis pain in patients undergoing radiation therapy to the head and neck. Clin J Oncol Nurs 2016;20:623–628. [CrossRef] [PubMed] [Google Scholar]
  55. Wiklund L, Sharma A, Sharma HS. Neuroprotection by methylene blue in cerebral global ischemic injury induced blood-brain barrier disruption and brain pathology: a review. CNS Neurol Disord Drug Targets 2016;15:1181–1187. [Google Scholar]
  56. Miclescu A. Chronic pain patient and anaesthesia. Rom J Anaesth Intensive Care 2019;26:59–66. [PubMed] [Google Scholar]
  57. Oz M, Lorke DE, Hasan M, Petroianu GA. Cellular and molecular actions of methylene blue in the nervous system. Med Res Rev 2011;31:93–117. [PubMed] [Google Scholar]
  58. Wainwright M, Crossley KB. Methylene Blue − a therapeutic dye for all seasons? J Chemother 2002;14:431–443. [CrossRef] [PubMed] [Google Scholar]
  59. Frankenburg FR, Baldessarini RJ. Neurosyphilis, malaria, and the discovery of antipsychotic agents. Harv Rev Psychiatry 2008;16:299–307. [CrossRef] [PubMed] [Google Scholar]
  60. Harvey BH, Duvenhage I, Viljoen F, Scheepers N, Malan SF, Wegener G, et al. Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues. Biochem Pharmacol 2010;80:1580–1591. [CrossRef] [PubMed] [Google Scholar]
  61. Akazawa M, Wu Y-H, Liu W-M. Allergy-like reactions to methylene blue following laparoscopic chromopertubation: a systematic review of the literature. Eur J Obstet Gynecol Reprod Biol 2019;238:58–62. [CrossRef] [PubMed] [Google Scholar]
  62. Farrokhi MR, Yazdanpanah H, Gholami M, Farrokhi F, Mesbahi AR. Pain and functional improvement effects of methylene blue injection on the soft tissue around fusion site after traumatic thoracolumbar fixation: A double-blind, randomized placebo-controlled study. Clin Neurol Neurosurg 2016;150:6–12. [CrossRef] [PubMed] [Google Scholar]
  63. Warrick BJ, Tataru AP, Smolinske S. A systematic analysis of methylene blue for drug-induced shock. Clin Toxicol (Phila) 2016;54:547–555. [PubMed] [Google Scholar]
  64. Cvetković BR, Cvetković VR, Rosić ZV, Milenković D. Late methylene blue appearance in urine after local treatment of cutaneous fistula in hip osteomyelitis as a firs sign of renal failure. Acta Chirurgica Iugoslavica 2008;55:117–120. [CrossRef] [PubMed] [Google Scholar]
  65. Paszynska E, Dmitrzak-Weglarz M, Roszak M, Boucher Y, Dutkiewicz A, Tyszkiewicz-Nwafor M, et al. Salivary opiorphin levels in anorexia nervosa: a case control study. World J Biol Psychiatry 2018:1–18. [PubMed] [Google Scholar]
  66. Sharr MM, Weller RO, Brice JG. Spinal cord necrosis after intrathecal injection of methylene blue. J Neurol Neurosurg Psychiatry 1978;41:384–386. [CrossRef] [PubMed] [Google Scholar]
  67. Youngster I, Arcavi L, Schechmaster R, Akayzen Y, Popliski H, Shimonov J, et al. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 2010;33:713–726. [CrossRef] [PubMed] [Google Scholar]
  68. Cragan JD. Teratogen update: methylene blue. Teratology 1999;60:42–48. [PubMed] [Google Scholar]
  69. Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol 2007;152:946–951. [CrossRef] [PubMed] [Google Scholar]
  70. Bartoshuk LM, Duffy VB, Miller IJ. PTC/PROP tasting: anatomy, psychophysics, and sex effects. Physiol Behav 1994;56:1165–1171. [CrossRef] [PubMed] [Google Scholar]
  71. Kullaa-Mikkonen A, Koponen A, Seilonen A. Quantitative study of human fungiform papillae and taste buds: variation with aging and in different morphological forms of the tongue. Gerodontics 1987;3:131–135. [Google Scholar]
  72. Miller IJ, Reedy FE. Variations in human taste bud density and taste intensity perception. Physiol Behav 1990;47:1213–1219. [CrossRef] [PubMed] [Google Scholar]
  73. Gremeau-Richard C, Woda A, Navez ML, Attal N, Bouhassira D, Gagnieu MC, et al. Topical clonazepam in stomatodynia: a randomised placebo-controlled study. Pain 2004;108:51–57. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.